T1	intervention 0 24	Intraoperative ketorolac
T2	eligibility 662 813	breast cancer patients, planned for curative surgery, and with a Neutrophil-to-Lymphocyte Ratioâ‰¥4, node-positive disease or a triple-negative phenotype
T3	outcome-Measure 840 880	Disease-Free Survival (DFS) at two years
T6	total-participants 994 997	203
T7	intervention-participants 1039 1041	96
T8	control 1046 1053	placebo
T9	control-participants 1059 1062	107
T10	outcome 1204 1226	alive and disease free
T11	iv-bin-percent 1177 1182	83.1%
T12	cv-bin-percent 1248 1253	89.7%
T15	iv-bin-percent 1321 1326	96.8%
T16	cv-bin-percent 1331 1336	98.1%
T17	outcome 1342 1347	alive
T5	outcome 1470 1491	disease-free survival
T13	outcome 1529 1545	Overall survival
T4	outcome-Measure 911 917	safety
T14	outcome-Measure 919 934	pain assessment
T18	outcome-Measure 939 955	overall survival
T19	age 1144 1161	55.7 (SD14) years
